Tuesday, 7 March 2017


Lupin today announced that the company has launched generic Paxil CR (Paroxetin) Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg. The pharma major has received an approval from the USFDA earlier.

The tablets are the AB rated generic equivalents of Apotex Technologies' Paxil CR Tablets, 12.5 mg, 25 mg and 37.5 mg. The tablets are mainly used for the treatment of major mental disorders, panic, social anxiety disorder and premenstrual dysphoric disorder.
The Paxil CR Tablets achieved US sales of USD 126.4 million (IMS MAT December 2016).

The stocks of Lupin on the NSE are trading in red, down by 1%, and in a period of one year have delivered negative returns of 17%, thereby underperforming the BSE Sensex and BSE Healthcare index over the same period of time.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

0 comments: